XCR Diagnostics and Luminex Enter into License Agreement
October 30, 2018
Xtreme Chain Reaction amplification technology provides new
capabilities for Luminex molecular diagnostic products
SALT LAKE CITY–(BUSINESS WIRE)–Privately held XCR Diagnostics Inc. and Luminex Corporation
(Nasdaq:LMNX) have entered into a non-exclusive, worldwide license
agreement for XCR’s proprietary Xtreme
Chain Reaction nucleic acid amplification technology. The XCR
technology enables extremely rapid thermal cycling protocols to achieve
dramatically reduced assay turnaround times compared to traditional
polymerase chain reaction. Financial terms were not disclosed.
“XCR Diagnostics is a young company developing a novel Portable Nucleic
Acid Testing System (pNATS™). We are excited about the confidence
Luminex has in using our XCR technology. This partnership will expose
more healthcare professionals to the benefits of using our proprietary
XCR technology,” said Mark Powelson, CEO of XCR Diagnostics.
“Luminex is committed to continuing to expand its technology
capabilities to deliver innovative solutions to our customers. We look
forward to leveraging the benefits that the XCR technology can bring to
our future molecular diagnostics portfolio,” said Homi Shamir, President
and CEO of Luminex Corporation.
About XCR Diagnostics, Inc.
XCR
Diagnostics Inc. is an early stage nucleic acid system company
advancing near patient portable molecular diagnostics instrumentation,
sample preparation and delivery plus detection and analysis to the
diagnostic markets; domestically and internationally. The company is
positioned to provide the first sub-10-minute to a negative test result
to the market, meaning a positive result could be as rapid as 7 to 8
minutes. The combination of small portable platforms and revolutionary
molecular reagents enables XCR Diagnostics to dramatically trim test
times and reduce healthcare costs, with a vision to deliver
hyper-accurate molecular diagnostics testing near patient and central
laboratory. Fluoresentric
Inc., a wholly owned XCR Diagnostics company, holds industry-leading
Intellectual Property (IP) and maintains commercial operations in the
food safety, veterinary and research markets. The company continues to
expand its IP claims as well as write new patients for submission to the
United States Patent and Trademark Office. To learn more about XCR
Diagnostics, please visit us at www.xcrdiagnostics.com.
About Luminex Corporation
At Luminex, our mission is to empower labs to obtain reliable, timely
and actionable answers, ultimately advancing health. We offer a wide
range of solutions applicable in diverse markets including clinical
diagnostics, pharmaceutical drug discovery, biomedical research, genomic
and proteomic research, biodefense research, and food safety. We
accelerate reliable answers while simplifying complexity and deliver
certainty with a seamless experience. To learn more about Luminex,
please visit us at www.luminexcorp.com.
Contacts
XCR Diagnostics, Inc.
Mark Powelson
President and CEO
mpowelson@xcrdiagnostics.com
or
Luminex
Corporation
Christine Valle, 512.219.8020
Sr. Manager, Global
Marketing Communications
cvalle@luminexcorp.com